

L1 0 S US 20060210624/PN
L2 0 S US 20060210624/PN

FILE 'REGISTRY' ENTERED AT 15:32:38 ON 05 JUL 2009

E OLANZAPINE/RN
E OLANZAPINE/CN
SET EXPAND CONTINUOUS
L3 1 S E3
E BF2649/CN
E BF 2649/CN
L4 1 S E27
E RISPERIDONE/CN
L5 1 S E39
E ARIPIPRAZOLE/CN
L6 1 S E51

FILE 'CAPLUS' ENTERED AT 15:35:35 ON 05 JUL 2009

L7 1 S L3 AND L4
L8 1452 S L3 AND (L5 OR L6)
L9 357 S L8 AND (PY<2003 OR AY<2003 OR PRY<2003)
L10 245 S L8 AND (SIDE EFFECT?)
L11 231 S L10 AND (?PSYCHOTIC? OR ?DEPRESSANT?)
L12 67 S L11 AND (APPETITE? OR WEIGHT?)
L13 11 S L12 AND (PY<2003 OR AY<2003 OR PRY<2003)
L14 1 S L4 AND (L5 OR L6)
L15 2 S L4 AND (?DEPRESSANT? OR ?PSYCHOTIC? OR NEUROLEPTIC?)
L16 2 S L4 AND (ANTIDEPRESSANT? OR ANTIPSYCHOTIC?)
L17 0 S L16 AND (PY<2003 OR AY<2003 OR PRY<2003)
L18 0 S L4 AND (WEIGHT (L) GAIN?)
L19 1 S L4 AND (APPETITE? OR WEIGHT?)
L20 1 S L4 AND (OBES? OR OVERWEIGHT?)
L21 0 S L20 NOT L19
L22 3 S L4 AND (COGNIT?)
L23 0 S L22 AND (PY<2003 OR AY<2003 OR PRY<2003)
L24 2 S L4 AND (?ANXIETY OR ?ANXIO? OR ?PSYCH?)
L25 0 S L24 AND (PY<2003 OR AY<2003 OR PRY<2003)
L26 0 S L4 AND (?EMOTION? OR NEUROLOGIC?)
L27 5 S L4
L28 0 S L4 AND (PY,2003 OR AY<2003 OR PRY<2003)
L29 0 S L4 AND (PY<2003 OR AY<2003 OR PRY<2003)

FILE 'REGISTRY' ENTERED AT 15:50:35 ON 05 JUL 2009

E CIPROXIDINE/CN
L30 1 S E63

E BF 2649/CN
SET EXPAND CONTINUOUS
L1 1 S E3
L2 STRUCTURE UPLOADED
L3 1425 S L2 SSS FULL

FILE 'CAPLUS' ENTERED AT 07:53:22 ON 06 JUL 2009

L4 170 S L3
L5 10 S L3 AND HISTAMINE?
L6 8 S L5 AND (PY<2003 OR AY<2003 OR PRY<2003)

FILE 'REGISTRY' ENTERED AT 07:55:44 ON 06 JUL 2009


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2856596	A1	20041231	FR 2003-7836	
20030627				
FR 2856596	B1	20070427		
CA 2530381	A1	20050106	CA 2004-2530381	
20040625				
WO 2005000315	A1	20050106	WO 2004-FR1628	
20040625				
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA,				
CH,				

GD, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB,
 LC, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,
 NI, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
 SY, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,
 ZW TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
 AM, RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
 DK, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE,
 SE, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO,
 NE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
 SN, TD, TG
 EP 1641461 A1 20060405 EP 2004-767475
 20040625 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,
 PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
 JP 2007516160 T 20070621 JP 2006-516331
 20040625
 MX 2005013877 A 20060313 MX 2005-13877
 20051216
 US 20060210624 A1 20060921 US 2005-562396
 20051227
 PRIORITY APPLN. INFO.: FR 2003-7836 A
 20030627 WO 2004-FR1628 W
 20040625

FILE 'REGISTRY' ENTERED AT 08:03:23 ON 06 JUL 2009
 L16 1 S 5786-21-0/RN

L16 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN
 RN 5786-21-0 REGISTRY
 CN 5H-Dibenzo[b,e][1,4]diazepine, 8-chloro-11-(4-methyl-1-
 piperazinyl)- (CA
 INDEX NAME)
 OTHER NAMES:
 CN 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine
 CN Asaleptin
 CN Azaleptine
 CN Cloril
 CN Clozapin
 CN Clozapine
 CN Clozaril
 CN Fazaclo
 CN HF 1854
 CN Iprox
 CN Klozapol

CN Leponex
 MF C18 H19 Cl N4
 CI COM
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
 BIOSIS,
 BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN,
 CSCHEM,
 DDFU, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH,
 IMSDRUGNEWS, IMSPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MEDLINE,
 MRCK*,
 PHAR, PROMT, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, USAN,
 USPAT2,
 USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: EINECS**, WHO
 (**Enter CHEMLIST File for up-to-date regulatory information)
 DT.CA CAPLUS document type: Book; Conference; Dissertation; Journal;
 Patent;
 Report
 RL.P Roles from patents: ANST (Analytical study); BIOL (Biological
 study);
 PREP (Preparation); PROC (Process); PRP (Properties); PRPH
 (Prophetic);
 RACT (Reactant or reagent); USES (Uses)
 RLD.P Roles for non-specific derivatives from patents: BIOL
 (Biological
 study); FORM (Formation, nonpreparative); PREP (Preparation);
 PROC
 (Process); PRP (Properties); USES (Uses)
 RL.NP Roles from non-patents: ANST (Analytical study); BIOL
 (Biological
 study); FORM (Formation, nonpreparative); MSC (Miscellaneous);
 OCCU
 (Occurrence); PREP (Preparation); PROC (Process); PRP
 (Properties); RACT
 (Reactant or reagent); USES (Uses)
 RLD.NP Roles for non-specific derivatives from non-patents: ANST
 (Analytical
 study); BIOL (Biological study); FORM (Formation,
 nonpreparative); PREP
 (Preparation); PROC (Process); PRP (Properties); USES (Uses)




SET NOTICE 1 DISPLAY
 SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 08:03:38 ON 06 JUL 2009
 L17 1 S 85650-52-8/RN

L17 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN
 RN 85650-52-8 REGISTRY
 CN Pyrazino[2,1-a]pyrido[2,3-c][2]benzazepine,
 1,2,3,4,10,14b-hexahydro-2-methyl- (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Pyrazino[2,1-a]pyrido[2,3-c][2]benzazepine,
 1,2,3,4,10,14b-hexahydro-2-methyl-, (±)-
 OTHER NAMES:
 CN 6-Azamianserin
 CN Avanza
 CN Mepirzapin
 CN Mepirzepine
 CN Mirtabene
 CN Mirtaz 15
 CN Mirtazapine
 CN Mirtazepine
 CN Mirtazipine
 CN Norset
 CN Org 3770
 CN Promyrtil
 CN Remergil
 CN Remergon
 CN Remeron
 CN Rexer
 CN Zispin
 DR 61337-67-5, 82601-27-2
 MF C17 H19 N3
 CI COM
 SR European Union (EU)
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
 BIOSIS,
 BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN,
 CSCHEM,
 DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH,
 IMSDRUGNEWS,
 IMSPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-
 OHS,
 PHAR, PIRA, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER,
 USAN,
 USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: EINECS**, WHO
 (**Enter CHEMLIST File for up-to-date regulatory information)
 DT.CA Caplus document type: Book; Conference; Dissertation; Journal;
 Patent;
 Report
 RL.P Roles from patents: ANST (Analytical study); BIOL (Biological
 study);
 PREP (Preparation); PROC (Process); PRP (Properties); RACT
 (Reactant or
 reagent); USES (Uses); NORL (No role in record)
 RLD.P Roles for non-specific derivatives from patents: ANST
 (Analytical

study); BIOL (Biological study); PRP (Properties); USES (Uses)
 RL.NP Roles from non-patents: ANST (Analytical study); BIOL
 (Biological
 study); OCCU (Occurrence); PREP (Preparation); PROC (Process);
 PRP
 (Properties); RACT (Reactant or reagent); USES (Uses)
 RLD.NP Roles for non-specific derivatives from non-patents: BIOL
 (Biological
 study); PREP (Preparation)




SET NOTICE 1 DISPLAY
 SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 08:03:55 ON 06 JUL 2009
 L18 1 S 106266-06-2/RN

L18 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN
 RN 106266-06-2 REGISTRY
 CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl- (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN 1,2-Benzisoxazole, 4H-pyrido[1,2-a]pyrimidin-4-one deriv.
 OTHER NAMES:
 CN Apexidone
 CN Psychodal
 CN R 64766
 CN Rispadal
 CN Risperdal
 CN Risperdal Consta
 CN Risperidal
 CN Risperidone
 CN Spiron
 MF C23 H27 F N4 O2
 CI COM
 SR CA
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DDFU, DRUGU, EMBASE, HSDB*, IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MEDLINE, MRCK*, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
 (*File contains numerically searchable property data)

Other Sources: WHO
 DT.CA CAPLUS document type: Book; Conference; Dissertation; Journal; Patent
 RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study);
 PREP (Preparation); PROC (Process); PRP (Properties); PRPH (Prophetic);
 RACT (Reactant or reagent); USES (Uses)
 RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); MSC (Miscellaneous); NANO (Nanomaterial); OCCU (Occurrence);
 PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
 RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological study); PROC (Process); PRP (Properties); USES (Uses)



SET NOTICE 1 DISPLAY
 SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 08:04:11 ON 06 JUL 2009
 L19 1 S 111974-69-7/RN

L19 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN
 RN 111974-69-7 REGISTRY
 CN Ethanol, 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]-
 (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Dibenzo[b,f][1,4]thiazepine, ethanol deriv.

OTHER NAMES:

CN Quetiapine

DR 264256-90-8

MF C21 H25 N3 O2 S

CI COM

SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, CA, CAPLUS,

CASREACT, CBNB, CHEMCATS, CIN, DDFU, DRUGU, HSDB*, IMSDRUGNEWS, IMSPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MRCK*, PATDPASPC, PHAR, PROMT,

PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2,

USPATFULL

(*File contains numerically searchable property data)

DT.CA CAPIus document type: Book; Conference; Dissertation; Journal; Patent

RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study);

FORM (Formation, nonpreparative); PREP (Preparation); PROC (Process);

PRP (Properties); PRPH (Prophetic); RACT (Reactant or reagent); USES

(Uses)

RLD.P Roles for non-specific derivatives from patents: BIOL (Biological

study); PREP (Preparation); PROC (Process); PRP (Properties);

USES


(Uses)

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological

study); OCCU (Occurrence); PREP (Preparation); PROC (Process);

PRP

(Properties); RACT (Reactant or reagent); USES (Uses)



SET NOTICE 1 DISPLAY

SET NOTICE LOGIN DISPLAY


FILE 'REGISTRY' ENTERED AT 08:04:44 ON 06 JUL 2009
L20 1 S 132539-06-1/RN

L20 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN
RN 132539-06-1 REGISTRY
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(CA INDEX NAME)

OTHER NAMES:

CN Lanza
CN LY 170053
CN Olanzapine
CN Oleanz
CN Oliza
CN Olta
CN Zyprexa
DR 1034315-19-9
MF C17 H20 N4 S

CI COM
 SR US Adopted Names Council (USAN)
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS,
 BIOTECHNO,
 CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DDFU, DRUGU,
 EMBASE,
 IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS, IMSPRODUCT, IMSRESEARCH,
 IPA,
 MEDLINE, MRCK*, PATDPASPC, PHAR, PIRA, PROMT, PROUSDDR, PS,
 RTECS*,
 SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 DT.CA Caplus document type: Conference; Dissertation; Journal; Patent
 RL.P Roles from patents: ANST (Analytical study); BIOL (Biological
 study);
 FORM (Formation, nonpreparative); PREP (Preparation); PROC
 (Process);
 PRP (Properties); PRPH (Prophetic); RACT (Reactant or reagent);
 USES
 (Uses)
 RLD.P Roles for non-specific derivatives from patents: BIOL
 (Biological
 study); FORM (Formation, nonpreparative); PREP (Preparation); PRP
 (Properties); RACT (Reactant or reagent); USES (Uses)
 RL.NP Roles from non-patents: ANST (Analytical study); BIOL
 (Biological
 study); MSC (Miscellaneous); OCCU (Occurrence); PREP
 (Preparation); PROC
 (Process); PRP (Properties); RACT (Reactant or reagent); USES
 (Uses)
 RLD.NP Roles for non-specific derivatives from non-patents: BIOL
 (Biological
 study); FORM (Formation, nonpreparative); PREP (Preparation);
 PROC
 (Process); RACT (Reactant or reagent)




SET NOTICE 1 DISPLAY
 SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 08:05:12 ON 06 JUL 2009
 L21 1 S 288-32-4/RN
 SET NOTICE 1 DISPLAY
 SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 08:05:30 ON 06 JUL 2009
L22 1 S 362665-56-3/RN

L22 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN
RN 362665-56-3 REGISTRY
CN Piperidine, 1-[3-[3-(4-chlorophenyl)propoxy]propyl]- (CA INDEX
NAME)
OTHER NAMES:
CN 1-[3-[3-(4-Chlorophenyl)propoxy]propyl]piperidine
CN 3-(4-Chlorophenyl)propyl 3-piperidinopropyl ether
CN Pitolisant
MF C17 H26 Cl N O
CI COM
SR CA
LC STN Files: ADISINSIGHT, CA, CAPLUS, CASREACT, IMSDRUGNEWS,
IMSRESEARCH,
PROUSDDR, SYNTHLINE, TOXCENTER, USAN, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation);
RACT
(Reactant or reagent); USES (Uses)
RLD.P Roles for non-specific derivatives from patents: BIOL
(Biological
study); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); USES (Uses)



SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY

FILE 'CAPLUS' ENTERED AT 08:06:52 ON 06 JUL 2009
L23 10 S L22
L24 1 S L23 AND (PY<2003 OR AY<2003 OR PRY<2003)
L25 9189 S L16-L20
L26 2 S L23 AND L25

L26 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
TI Preparation of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidine
monohydrochloride as a histamine H3 receptor ligand.
ACCESSION NUMBER: 2006:817672 CAPLUS Full-text
DOCUMENT NUMBER: 145:249105
TITLE: Preparation of
1-[3-[3-(4-
chlorophenyl)propoxy]propyl]piperidine
monohydrochloride as a histamine H3 receptor
ligand.
INVENTOR(S): Raga, Manuel, M.; Sallares, Juan; Guerrero,
Marta;
Guglietta, Antonio
PATENT ASSIGNEE(S): Ferrer Internacional, S. A., Spain
SOURCE: PCT Int. Appl., 45pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
---	---	---	---	---
WO 2006084833	A1	20060817	WO 2006-EP50703	
20060206				
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

L26 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN

TI New psychiatric drug formulation with an antipsychotic or antidepressant

and an histamine H3 receptor antagonist for the prevention of psychotropic adverse effects

ACCESSION NUMBER: 2005:589 CAPLUS Full-text

DOCUMENT NUMBER: 142:79960

TITLE: New psychiatric drug formulation with an

antipsychotic

or antidepressant and an histamine H3 receptor antagonist for the prevention of psychotropic

adverse

effects

INVENTOR(S): Schwartz, Jean Charles; Rousseau Lecomte, Jeanne Marie

PATENT ASSIGNEE(S): Bioprojet, Fr.

SOURCE: Fr. Demande, 32 pp.

CODEN: FRXXBL

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

FR 2856596	A1	20041231	FR 2003-7836
20030627			
FR 2856596	B1	20070427	
CA 2530381	A1	20050106	CA 2004-2530381
20040625			
WO 2005000315	A1	20050106	WO 2004-FR1628
20040625			

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, SN, TD, TG

L27 0 S L26 AND (PY<2003 OR AY<2003 OR PRY<2003)
L28 2840 S L20
L29 85 S L20 AND HISTAMINE?
L30 152 S L20 AND ?HISTAMINE?
L31 41 S L30 AND (PY<2003 OR AY<2003 OR PRY<2003)

L31 ANSWER 10 OF 41 CAPLUS COPYRIGHT 2009 ACS on STN
TI Substance to prevent or reverse weight gain induced by psychoactive agents

ACCESSION NUMBER: 2003:396456 CAPLUS Full-text
DOCUMENT NUMBER: 138:379255
TITLE: Substance to prevent or reverse weight gain induced by

psychoactive agents
INVENTOR(S): Miller, Jon M.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 5 pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

US 20030096808 A1 20030522 US 1999-280279
19990329 <--
PRIORITY APPLN. INFO.: US 1999-280279
19990329 <--

AB A substance to prevent or reverse weight gain induced by psychoactive agents comprises an antipsychotic drug or mood stabilizing drug in a concentration from 0.01% to 99.99% in combination with a histamine H2-receptor antagonist in a concentration from 99.99% to 0.01%. Example antipsychotic drugs are olanzapine, clozapine, risperidone, and quetiapine. The antipsychotic drug is typically in a concentration of 10% to 90%, 30% to 60% and 50%. Example mood stabilizing drugs are divalproex sodium, valproic acid, and mirtazapine. The mood stabilizing drug is typically in a concentration of 10% to 90%, 30% to 60% and 50%. Example histamine H2-receptor antagonist are nizatidine, famotidine, cimetidine and ranitidine. The histamine H2-receptor antagonist (16) is typically in a concentration of 60% to 30% and 50%.

IC ICM A61K031-551

L31 ANSWER 24 OF 41 CAPLUS COPYRIGHT 2009 ACS on STN

TI Bodyweight gain with atypical antipsychotics: A comparative review
ACCESSION NUMBER: 2001:141908 CAPLUS Full-text
DOCUMENT NUMBER: 135:161867
TITLE: Bodyweight gain with atypical antipsychotics: A comparative review
AUTHOR(S): Wetterling, Tilman
CORPORATE SOURCE: Department of Psychiatry and Psychotherapy, Johann

Wolfgang Goethe University, Frankfurt, Germany
SOURCE: Drug Safety (2001), 24(1), 59-73
CODEN: DRSAEA; ISSN: 0114-5916
PUBLISHER: Adis International Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review with 93 refs. The atypical antipsychotics have been shown to have superior efficacy compared with typical antipsychotics such as haloperidol, particularly in the treatment of neg. symptoms of schizophrenia. Furthermore, they induce less extrapyramidal effects. However, following clin. use, marked bodyweight gain has been frequently observed with some of the atypical antipsychotic drugs. In order to examine and compare the frequency, amount and conditions of bodyweight gain during treatment with atypical antipsychotics, studies concerning bodyweight gain with these agents were identified through a MEDLINE search from 1966 to Mar. 2000. Although comparison is limited by the different designs and recruitment procedures of the reviewed studies, the available data support the notion that the frequency as well as the amount of bodyweight gain is high in patients treated with olanzapine (average bodyweight gain 2.3 kg/mo), clozapine (1.7 kg/mo), quetiapine (1.8 kg/mo), and possibly also zotepine (2.3 kg/mo). Moderate changes in bodyweight have been observed in the treatment with risperidone (average bodyweight gain 1.0 kg/mo). Ziprasidone seems to induce only slight bodyweight changes (0.8 kg/mo). Bodyweight gain most frequently occurs in the first 12 wk of treatment. Patients who

were underweight at the beginning of treatment are at highest risk, of gaining bodyweight. The underlying pathomechanism still remains largely unclear. The relative receptor affinities of the atypical antipsychotics for histamine H1 receptors as well as the ratio of their affinity for serotonin 5-HT2 and dopamine D2 receptors appear to be the most robust correlate of bodyweight gain. Furthermore, the induction of leptin secretion may have an important impact on bodyweight gain in patients treated with atypical antipsychotics. Although many questions concerning the pathogenesis of bodyweight gain remain unresolved, this adverse effect has to be taken into consideration when prescribing the atypical antipsychotics, particularly in view its affect on compliance during long term treatment and the long term effects of obesity on mortality and morbidity.

L31 ANSWER 26 OF 41 CAPLUS COPYRIGHT 2009 ACS on STN
 TI Combination for treating weight gain associated with antipsychotic use
 comprising an atypical antipsychotic and an H2 antagonist
 ACCESSION NUMBER: 2000:881023 CAPLUS Full-text
 DOCUMENT NUMBER: 134:33017
 TITLE: Combination for treating weight gain associated with
 antipsychotic use comprising an atypical
 antipsychotic and an H2 antagonist
 INVENTOR(S): Todd, Jane Rogers
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 43 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000074784	A1	20001214	WO 2000-US9811	
20000522 <--				
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1189662	A1	20020327	EP 2000-931932	
20000522 <--				

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,
PT,
IE, SI, LT, LV, FI, RO

L31 ANSWER 29 OF 41 CAPLUS COPYRIGHT 2009 ACS on STN
TI H2 antagonist nizatidine may control olanzapine-associated weight
gain in

schizophrenic patients
ACCESSION NUMBER: 2000:489015 CAPLUS Full-text
DOCUMENT NUMBER: 134:13255
TITLE: H2 antagonist nizatidine may control
olanzapine-associated weight gain in

schizophrenic

patients
AUTHOR(S): Sacchetti, E.; Guarneri, L.; Bravi, D.
CORPORATE SOURCE: University Psychiatric Service, University
School of
SOURCE: Medicine & Spedali Civili, Brescia, Italy
Biological Psychiatry (2000), 48(2), 167-168
CODEN: BIPCBF; ISSN: 0006-3223
PUBLISHER: Elsevier Science Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Background: Olanzapine is temporally associated, in a number of
patients with schizophrenia, with weight gain. H2 antagonists,
like nizatidine, have been shown to control appetite in overweight
patients. Methods: A patient with olanzapine temporally
associated weight gain was treated with nizatidine as "add-on"
therapy. Results: Nizatidine treatment was associated with good
control and subsequent reduction of weight after 4 to 5 wk of
therapy in a patient with repetitive episodes of weight gain
during olanzapine treatment. Olanzapine was otherwise well
tolerated and effective in controlling psychopathol. Conclusions:
H2 antagonist treatment with olanzapine may be a valid medical
strategy in preventing and/or reducing weight gain in patients
with schizophrenia. Controlled studies are recommended to confirm
this observation.

CC 1-11 (Pharmacology)

ST nizatidine histamine antagonist antiobesity olanzapine
schizophrenia

IT Antihistamines

(H2; H2 antagonist nizatidine may control olanzapine-associated
weight gain
in schizophrenic humans)

IT 132539-06-1, Olanzapine

RL: ADV (Adverse effect, including toxicity); THU (Therapeutic
use); BIOL

(Biological study); USES (Uses)

(H2 antagonist nizatidine may control olanzapine-associated
weight gain in
schizophrenic humans)

=> e schwartz jean?/au

E121 1 SCHWARTZ JEAN P/AU

E122 4 SCHWARTZ JEAN PIERRE/AU

```

E123      0 --> SCHWARTZ JEAN?/AU
E124      5      SCHWARTZ JEANNA/AU
E125      5      SCHWARTZ JEFF/AU
E126      2      SCHWARTZ JEFFERY/AU
E127      1      SCHWARTZ JEFFERY H/AU
E128      7      SCHWARTZ JEFFERY L/AU
E129      1      SCHWARTZ JEFFERY S/AU
E130      1      SCHWARTZ JEFFFREY/AU
E131      274    SCHWARTZ JEFFREY/AU
E132      1      SCHWARTZ JEFFREY A/AU

```

```

=> e lecomte jeanne?/au

```

```

E133      7      LECOMTE JEANNE M/AU
E134      72     LECOMTE JEANNE MARIE/AU
E135      0 --> LECOMTE JEANNE?/AU
E136      13     LECOMTE JEROME/AU
E137      1      LECOMTE JOAN/AU
E138      1      LECOMTE JOSEPH/AU
E139      1      LECOMTE JOULIN V/AU
E140      5      LECOMTE JULIE/AU
E141      2      LECOMTE JULIETTE/AU
E142      1      LECOMTE JULIETTE T/AU
E143      76     LECOMTE JULIETTE T J/AU
E144      1      LECOMTE JULIETTE THERESE J/AU

```

```

=> s e133-e134

```

```

      7 "LECOMTE JEANNE M"/AU
      72 "LECOMTE JEANNE MARIE"/AU
L32      79 ("LECOMTE JEANNE M"/AU OR "LECOMTE JEANNE MARIE"/AU)

```

```

=> s l32 and histiamine?

```

```

      5 HISTIAMINE?
L33      0 L32 AND HISTIAMINE?

```

```

=> s l32 and (py<2003 or ay<2003 or pry<2003)

```

```

      22984276 PY<2003
      4508246 AY<2003
      3977805 PRY<2003
L34      62 L32 AND (PY<2003 OR AY<2003 OR PRY<2003)

```

```

=> s l32 and l23

```

```

L35      5 L32 AND L23

```

```

=> s l35 and (py<2003 or ay,2003 or pry<2003)

```

```

      22984276 PY<2003
      3432 AY
      40 AYS
      3472 AY
      (AY OR AYS)
      44526 2003
      0 AY,2003
      (AY(W)2003)
      3977805 PRY<2003
L36      1 L35 AND (PY<2003 OR AY,2003 OR PRY<2003)

```

```

=> s l35 and (py<2003 or ay<2003 or pry<2003)

```

```

      22984276 PY<2003

```


4508246 AY<2003
3977805 PRY<2003

L37 1 L35 AND (PY<2003 OR AY<2003 OR PRY<2003)